Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tonya Branning

Nurse Practitioner, Family Flowood, MS Nurse Practitioner

NPI 1952631731 CMS profile 11030115

104 Burney Dr., Flowood, MS 39232

Open in the dashboard

General payments

$8,954

103 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tonya Branning of Flowood, MS is reported in the CMS Open Payments database as having received $8,954 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,392 17
2024 General $990 14
2023 General $705 18
2022 General $4,040 32
2021 General $826 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tonya Branning
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Tonya Branning were reported at $2,392. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Tonya Branning Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $826 $124 $35–$379 $132
2022 $4,040 $141 $44–$430 $149
2023 $705 $154 $49–$476 $160
2024 $990 $165 $51–$504 $164
2025 $2,392 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Arthrex, Inc. $3,235 15 payments
  2. Treace Medical Concepts, Inc. $2,103 8 payments
  3. Stryker Corporation $1,760 18 payments
  4. Kowa Pharmaceuticals America, Inc. $202 10 payments
  5. Davol Inc. $165 3 payments
  6. Abbott Laboratories $139 2 payments
  7. Heron Therapeutics, Inc. $133 2 payments
  8. Lundbeck LLC $125 1 payment
  9. Sanara MedTech Inc. $124 1 payment
  10. Bioventus LLC $113 4 payments
  11. Other $854 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,621 92 payments
  2. Travel and Lodging $2,933 9 payments
  3. Education $2,400 2 payments
Products named General payments · program years 2021–2025
  1. LAPIPLASTY SYSTEM 1 $1,139 1 payment
  2. LAPIPLASTY $712 3 payments
  3. INFINITY ADAPTIS $367 3 payments
  4. AUGMENT INJECTABLE $351 3 payments
  5. INFINITY $289 2 payments
  6. PROSTEP $262 2 payments
  7. PRIME SERIES $172 1 payment
  8. INBONE $168 1 payment
  9. INVISION $163 3 payments
  10. Zynrelef $133 2 payments
  11. Other $2,200 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

358

Median for Nurse Practitioner: 389

Drug cost

$2,335

Median for Nurse Practitioner: $21,885

Branded share of claims

20.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 38 $458
Celecoxib Generic 17 $456
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 40 $324
Ketorolac Tromethamine Generic 19 $288
Meloxicam Generic 102 $221
Methylprednisolone Generic 31 $179
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 35 $134
Gabapentin Generic 33 $133
Mupirocin Generic 19 $91
Tramadol Hcl Generic 24 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 84 billing codes

Paid by Medicare

$67,611

Of which drugs: $19,345

Medicare patients

316

Average age 72

Services billed

6,056

230 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 28%
Ischemic heart disease 25%
Depression 25%
Osteoporosis 18%
Chronic kidney disease 16%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 42 4,680 $475

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record